GABA-A PAM for Anxiety
Anxiety Disorders
DiscoveryActive
Key Facts
About Modulate Bio
Modulate Bio is a private, pre-revenue biotech founded in 2021, leveraging a proprietary platform to design selective GABA-A PAMs for neurological disorders. The company is nearing a development candidate for Essential Tremor, its lead program, with a pipeline that includes epilepsy and anxiety. Backed by academic roots from Harvard and Brigham and Women's Hospital, the team combines deep drug discovery expertise with a clear focus on validated targets with significant unmet medical need.
View full company profileTherapeutic Areas
Other Anxiety Disorders Drugs
| Drug | Company | Phase |
|---|---|---|
| Anxiety Clinical Trials | Boston Clinical Trials | Not Specified (Typically Phase 2-3) |
| Anxiety Disorders Biomarker Services | The Siesta Group | Service Offering |
| Supera-CBD | TNF Pharmaceuticals | Preclinical |
| TLR-007 | Tilray | Phase 1/2 |
| LYT-300 | PureTech Health | Phase 1 |
| CTx-2103 | Cingulate | Preclinical |